Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry

Gellekom, Marion P.R. Van; Moerland, Marinus A.; Vulpen, Marco van; Wijrdeman, Harm K.; Battermann, Jan J.

doi:10.1016/j.ijrobp.2005.03.046

Cited by 61 publications

(35 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, QoL after permanent prostate brachytherapy in relation to dosimetry (10) and the influence of adding hyperthermia to radiotherapy on QoL (11) have been described. The purpose of this study was to investigate the QoL changes after dose-escalated radiotherapy.…”

Section: Introductionmentioning

confidence: 99%

Health-Related Quality of Life in Patients With Locally Advanced Prostate Cancer After 76 Gy Intensity-Modulated Radiotherapy vs. 70 Gy Conformal Radiotherapy in a Prospective and Longitudinal Study

Lips

Dehnad

Kruger

et al. 2007

International Journal of Radiation Oncology*Biology*Physics

Self Cite

View full text Add to dashboard Cite

Purpose: To compare quality of life (QoL) after 70 Gy conformal radiotherapy with QoL after 76 Gy intensitymodulated radiotherapy (IMRT) in patients with locally advanced prostate carcinoma. Methods and Materials: Seventy-eight patients with locally advanced prostate cancer were treated with 70 Gy three-field conformal radiotherapy, and 92 patients received 76 Gy IMRT with fiducial markers for position verification. Quality of life was measured by RAND-36, the European Organization for Research and Treatment of Cancer core questionnaire (EORTC QLQ-C30(+3)), and the prostate-specific EORTC QLQ-PR25, before radiotherapy (baseline) and 1 month and 6 months after treatment. Quality of life changes in time (baseline vs. 1 month and baseline vs. 6 months) of $10 points were considered clinically relevant. Results: Differences between the treatment groups for QoL changes over time occurred in several QoL domains. The 76-Gy group revealed no significant deterioration in QoL compared with the 70-Gy group. The IMRT 76-Gy group even demonstrated a significantly better change in QoL from baseline to 1 month in several domains. The conformal 70-Gy group revealed temporary deterioration in pain, role functioning, and urinary symptoms; for the IMRT 76-Gy group a better QoL in terms of change in health existed after 1 month, which persisted after 6 months. For both treatment groups temporary deterioration in physical role restriction occurred after 1 month, and an improvement in emotional role restriction occurred after 6 months. Sexual activity was reduced after treatment for both groups and remained decreased after 6 months. Conclusions: Intensity-modulated radiotherapy and accurate position verification seem to provide a possibility to increase the radiation dose for prostate cancer without deterioration in QoL. Ó 2007 Elsevier Inc.

show abstract

Section: Introductionmentioning

confidence: 99%

Health-Related Quality of Life in Patients With Locally Advanced Prostate Cancer After 76 Gy Intensity-Modulated Radiotherapy vs. 70 Gy Conformal Radiotherapy in a Prospective and Longitudinal Study

Lips

Dehnad

Kruger

et al. 2007

International Journal of Radiation Oncology*Biology*Physics

Self Cite

View full text Add to dashboard Cite

show abstract

“…19 One year after implant, HRQOL of the patients was at least equal to preimplant scores, which suggests that many of the negative effects may recover in the long term. This confirms the reports that demonstrate that acute side effects after brachytherapy for prostate cancer appear to peak 1 month after brachytherapy and subsequently return to their baseline values at 1 year.…”

Section: Discussionmentioning

confidence: 90%

Health-Related Quality of Life in I-125 Prostate Brachytherapy Patients Treated with and without Volume-Reducing Hormone Therapy: Results of a Short-Term Prospective Study

Mols

Stijns

Dankaart

et al. 2009

Journal of Endourology

View full text Add to dashboard Cite

Health-related quality of life in I-125 prostate brachytherapy patients treated with and without volume-reducing hormone therapy Mols, Floortje; Stijns, P.; Dankaart, B.; Houterman, S.; Vingerhoets, Ad; Hendrikx, A.J.P. General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.-Users may download and print one copy of any publication from the public portal for the purpose of private study or research -You may not further distribute the material or use it for any profit-making activity or commercial gain -You may freely distribute the URL identifying the publication in the public portal Take down policyIf you believe that this document breaches copyright, please contact us providing details, and we will remove access to the work immediately and investigate your claim. AbstractPurpose: This study describes the differences in short-term effects of health-related quality of life (HRQOL) in I-125 prostate brachytherapy patients who were treated with and without volume-reducing hormone therapy. Patients and Methods: Prostate cancer patients (N ϭ 312) filled out questionnaires on HRQOL (European Organization of Research and Treatment of Cancer Quality of Life Questionnaire [EORTC-QLQ]-C30 and EORTC-QLQ-PR25) before treatment and 6 weeks and 3 months after treatment. HRQOL was compared between the two groups: Patients who were receiving brachytherapy (n ϭ 233) and patients who were receiving brachytherapy with volume-reducing hormone therapy (n ϭ 79). Duration of androgen ablation was 9 months, starting 3 months before I-125 implantation. Results: After treatment, patients reported significant and clinically relevant decreased scores on the following subscales: Global health status, role functioning, social functioning, pain, insomnia, bowel symptoms and functioning, and treatment-related functions, regardless of the therapy they received. Results showed that prostate cancer patients receiving brachytherapy with volume-reducing hormone therapy also experienced lower treatment-related functions and lower sexual function. Significant time by treatment interaction effects were found for treatment-related functions. The subscale treatment-related functions was the only scale that showed a difference over time, between treatments, and time by treatment. Conclusions: The differences in HRQOL between brachytherapy and brachytherapy with volume-reducing hormone therapy are small; they both decrease HRQOL and increase treatment-related problems. A long-term prospective study on long-term effects on HRQOL is needed to obtain a more comprehensive view of the consequences of a specific treatment modality over time. Our results can help to identify the problems patients face after brachytherapy with or without hormone therapy; these problems deserve additional attention during the period of recovery. 153

show abstract

“…Brachytherapy is complicated in 30-50% by obstructive voiding symptoms (OVS) within 12 months after brachytherapy [2,3]. OVS can be quantified using the international prostate symptom score (IPSS) [4].…”

Section: Introductionmentioning

confidence: 99%

“…OVS can be quantified using the international prostate symptom score (IPSS) [4]. Also a decrease in the urinary flow curve [4,5] and loss of quality of life [3] can be observed. Approximately 15% of the patients develop severe OVS and the incidence rate of urinary retention varies from 0 to 36% [4,6,7,8,9,10].…”

Section: Introductionmentioning

confidence: 99%

The Use of a Memokath Prostatic Stent for Obstructive Voiding Symptoms after Brachytherapy

Graaf¹,

Stijns²,

Scheepens³

et al. 2013

Current Urology

View full text Add to dashboard Cite

Introduction: Brachytherapy may be complicated by serious obstructive voiding symptoms (OVS). Only conservative treatment options are available in the first 6 months after brachytherapy. We evaluated safety, efficacy and patient tolerance of the Memokath prostatic stent (MPS). Material and Methods: A MPS was placed in 10 patients with OVS after brachytherapy. Evaluation included uroflowmetry, international prostate symptom score (IPSS), prostate volume and urethrocystoscopy before and 3 months after placement of the stent. Results: Both the IPSS and uroflowmetry results significantly improved after stent insertion. The mean IPSS decreased from 29/5 to 11/1 and the mean Qmax from the uroflowmetry improved from 4.7 to 11.2 ml/s. The 5 patients who were catheter dependent voided spontaneously with a mean Qmax of 15 ml/s. Two stents migrated towards the bladder, and those patients needed a second stent which was placed without complications. Removal of the stent was easy to perform. Adverse effects were minor with perineal pain and irritative voiding symptoms occurring in 5 patients mainly in the first weeks after insertion. This did not negatively influence quality of life and all patients were more satisfied with the stent than without. Conclusions: The MPS provides a safe, effective, and completely reversible treatment for patients with OVS after brachytherapy and was well tolerated.

show abstract

Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry

Cited by 61 publications

References 41 publications

Health-Related Quality of Life in Patients With Locally Advanced Prostate Cancer After 76 Gy Intensity-Modulated Radiotherapy vs. 70 Gy Conformal Radiotherapy in a Prospective and Longitudinal Study

Health-Related Quality of Life in Patients With Locally Advanced Prostate Cancer After 76 Gy Intensity-Modulated Radiotherapy vs. 70 Gy Conformal Radiotherapy in a Prospective and Longitudinal Study

Health-Related Quality of Life in I-125 Prostate Brachytherapy Patients Treated with and without Volume-Reducing Hormone Therapy: Results of a Short-Term Prospective Study

The Use of a Memokath Prostatic Stent for Obstructive Voiding Symptoms after Brachytherapy

Contact Info

Product

Resources

About